Meeting Overview - The second extraordinary general meeting of shareholders was held on November 21, 2025, at the company's conference room in Beijing [2] - The meeting was convened by the board of directors and chaired by Chairman Wu Shiming, utilizing a combination of on-site and online voting methods [2] Attendance - All 9 serving directors attended the meeting, with independent director Jiang Zheming participating via telecommunication [3] - All 3 serving supervisors were present, along with the board secretary and several deputy general managers [3] Resolutions Passed - The proposal to abolish the supervisory board and amend the Articles of Association was approved [4] - Multiple governance documents were revised and approved, including: - Amendments to the Rules of Procedure for Shareholders' Meetings [5] - Amendments to the Rules of Procedure for Board Meetings [5] - Amendments to the Compensation Management System for Directors, Supervisors, and Senior Management [5] - Amendments to the Independent Director System [5] - Amendments to the External Investment Management Measures [5] - Amendments to the Related Party Transaction Management Measures [5] - Amendments to the Financing and External Guarantee Management Measures [5] - Amendments to the Management System for Raised Funds [5] - The abolition of the Rules of Procedure for Supervisory Meetings and the Implementation Details of Cumulative Voting System for Shareholders' Meetings was also approved [6] Voting Details - The first proposal required a special resolution, needing more than two-thirds of the voting rights held by attending shareholders to pass, while other proposals required a simple majority [6] - Separate counting of votes was conducted for the first proposal concerning minority investors [6] Legal Verification - The meeting was witnessed by Beijing Zhonglun Law Firm, with lawyers confirming that the meeting's procedures and resolutions complied with legal and regulatory requirements [6]

北京市中伦律师事务所 关于北京赛科希德科技股份有限公司 2025 年第二次临时股东大会的 1. 现行有效的公司章程； 2. 公司刊登在上海证券交易所网站的公司董事会关于召开本次股东大会的 通知； 3. 公司本次股东大会股权登记日的股东名册、出席现场会议股东的到会登 记记录及凭证资料； 4. 公司本次股东大会的相关会议文件。 - 1 - 法律意见书 本法律意见书仅供公司为本次股东大会之目的使用，本所律师同意将本法律 意见书随同公司本次股东大会决议及其他信息披露资料一并公告。 法律意见书 致：北京赛科希德科技股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》等相关法律、法 规和规范性文件及《北京赛科希德科技股份有限公司章程》（以下简称"公司章 程"）的规定，北京市中伦律师事务所（以下简称"本所"）接受北京赛科希德 科技股份有限公司（以下简称"公司"）委托，对公司 2025 年第二次临时股东 大会（以下简称"本次股东大会"）的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的相关文件，该等文件包括 但不限于： 本所律师根据相关法律法规的要求，按照律师行业公认的业务标准、道 ...

证券代码：688338 证券简称：赛科希德 公告编号：2025-049 北京赛科希德科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 40 | | --- | --- | | 普通股股东人数 | 40 | | 2、出席会议的股东所持有的表决权数量 | 45,199,163 | | 普通股股东所持有表决权数量 | 45,199,163 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 42.5835 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 42.5835 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长吴仕明先生主持，会议采用现场投 票和网络投票相结合的 ...

证券日报网讯 11月17日晚间，赛科希德发布公告称，公司核心技术人员乐嘉敏先生达到法定退休年龄 后继续被公司返聘，现因本人年龄及身体原因于近日向公司申请不再继续返聘并已办理完成离职手续， 离职后不再担任公司任何职务。 （文章来源：证券日报） ...

Group 1 - Yongtai Technology's wholly-owned subsidiary has received approval for trial production of a lithium battery additive project with an annual capacity of 5,000 tons, set to begin trial production [1] - Mengke Pharmaceutical has decided to terminate its plan to issue shares to a specific entity due to ongoing disagreements among major shareholders, which could impact the company's stable operations [1] - Anhui Construction's subsidiary has been approved to register and issue debt financing tools totaling 15 billion yuan, including 5 billion yuan in short-term financing notes and 10 billion yuan in medium-term notes [2] Group 2 - Koli'er plans to repurchase shares worth between 10 million and 20 million yuan, with a maximum repurchase price of 20.94 yuan per share, to implement an employee stock ownership plan [2] - Xinhua Pharmaceutical has received approval for the production of fumaric acid volnoral raw materials, which are used to treat gastroesophageal reflux disease [3] - Lianhuan Pharmaceutical has received approval for additional specifications of tadalafil tablets, expanding its product offerings for treating erectile dysfunction and benign prostatic hyperplasia [5] Group 3 - Greenland Holdings reported an increase of 1,834 lawsuits with a total amount of 6.587 billion yuan from October 21 to November 13, 2025 [7] - Lianke Technology plans to invest up to 600 million yuan of idle funds in low-risk financial products [8] - Yinglian Co. signed a strategic procurement contract for 5,000 million square meters of composite aluminum foil with a leading new energy technology company [10] Group 4 - China Eastern Airlines reported a 10.58% year-on-year increase in passenger turnover for October, with a capacity increase of 6.84% [12] - China National Airlines reported an 8.7% year-on-year increase in passenger turnover for October, with domestic and international capacity also showing growth [15] - Oupai Home plans to use 320 million yuan of idle funds to purchase structured deposits with expected annual yields between 0.65% and 2.50% [16] Group 5 - Tianwei Food has submitted H-share issuance application materials to the Hong Kong Stock Exchange, which have been accepted by the China Securities Regulatory Commission [18] - Guizhou Aviation plans to establish a subsidiary focused on the research, production, and market expansion of intelligent automotive components, with initial operating funds of 40 million yuan [20] - Daimai Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary in Shanghai focused on robotics technology [22] Group 6 - Founder Securities has received approval to issue company bonds totaling up to 30 billion yuan [24] - Hengrui Medicine has received clinical trial approvals for multiple drugs, indicating ongoing research and development efforts [26] - Zhaojing Pharmaceutical's product ZG006 has received orphan drug designation from the FDA, providing various benefits for its development in the U.S. market [39]

证券代码：688338 证券简称：赛科希德 公告编号：2025-048 北京赛科希德科技股份有限公司 关于公司核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至本公告披露日，乐嘉敏先生直接持有公司股份 40,200 股, 占公司股份总 数的比例为 0.04%。离职后，乐嘉敏先生将继续遵守《上海证券交易所科创板股票 上市规则》等相关法律法规有关减持的规定，严格履行做出的各项承诺。 （二） 参与的研发项目和专利情况 乐嘉敏先生在职期间参与了公司的仪器研发指导工作，目前已完成工作交接， 公司产品与技术研发工作均正常开展。截至本公告披露日，乐嘉敏先生在公司任职 期间参与研发的授权专利所有权均归属于公司，不存在涉及职务发明专利权属纠纷 或潜在纠纷的情形，亦不存在影响公司专利权属完整性的情况。 北京赛科希德科技股份有限公司（以下简称"公司"）核心技术人员乐嘉敏 先生因本人年龄及身体原因于近日向公司申请不再继续返聘并已办理完成离职手 续，离职后不再担任公司任何职务。基于前述原因，公司不再认定乐嘉 ...

Group 1 - The core technical personnel, Mr. Le Jiamin, has applied for resignation due to age and health reasons, and has completed the departure procedures, no longer holding any position in the company [1] - For the fiscal year 2024, the revenue composition of the company is as follows: 99.67% from the pharmaceutical manufacturing industry and 0.33% from other businesses [1] - The current market capitalization of the company is 2.9 billion yuan [1]

Core Viewpoint - The departure of key technical personnel, Le Jiamin, due to age and health reasons, will not impact the company's core competitiveness and ongoing operations [1] Group 1: Personnel Changes - Le Jiamin has left the company and will no longer hold any position [1] - He directly held 40,200 shares, accounting for 0.04% of the company, and will reduce his holdings in accordance with regulations [1] - The company has completed the handover of his work and emphasizes that it does not rely on a single key technical personnel [1] Group 2: Company Strategy - The company will continue to enhance its research and development system and team building [1] - The ownership of relevant authorized patents remains with the company [1]

Core Viewpoint - The stock price of Saikexide has shown fluctuations, with a year-to-date increase of 14.13% but a recent decline of 2.01% in the last trading session, indicating potential volatility in the market [1][2]. Company Overview - Saikexide Technology Co., Ltd. is located in Daxing District, Beijing, and was established on May 28, 2003. The company was listed on August 6, 2020, and primarily engages in the research, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [2]. - The revenue composition of Saikexide includes reagents (53.71%), instruments (25.40%), consumables (20.58%), and other (0.31%) [2]. Financial Performance - For the period from January to September 2025, Saikexide reported a revenue of 196 million yuan, representing a year-on-year decrease of 13.62%. The net profit attributable to the parent company was approximately 64.56 million yuan, down 22.83% year-on-year [2]. - As of September 30, the number of shareholders increased by 3.44% to 7,012, while the average circulating shares per person decreased by 3.32% to 15,137 shares [2]. Market Activity - On November 17, Saikexide's stock price fell by 2.01%, trading at 27.24 yuan per share with a total market capitalization of 2.891 billion yuan. The trading volume was 8.4171 million yuan, with a turnover rate of 0.29% [1]. - The net outflow of main funds was 381,800 yuan, with large single purchases amounting to 224,600 yuan (2.67% of total) and sales of 606,400 yuan (7.20% of total) [1]. Dividend Information - Since its A-share listing, Saikexide has distributed a total of 136 million yuan in dividends, with 83.14 million yuan distributed over the past three years [3].

Core Viewpoint - The company, Beijing Suceeder Technology Co., Ltd., is set to hold a Q3 2025 performance briefing on December 2, 2025, to discuss its operational results and financial status with investors [1][2]. Group 1: Meeting Details - The performance briefing will take place on December 2, 2025, from 11:00 to 12:00 [4][5]. - The meeting will be conducted in an online interactive format via the Shanghai Stock Exchange Roadshow Center [4][5]. - Investors can submit questions in advance from November 25 to December 1, 2025, through the Roadshow Center's website or via the company's email [2][6]. Group 2: Participants - Key participants in the meeting will include the company's General Manager Wang Hai, Deputy General Manager Ding Zhonghui, Chief Financial Officer Li Guo, Independent Director Jiang Zheming, and Secretary of the Board Zhang Jiahong [3]. Group 3: Contact Information - Investors can contact the Board Office for inquiries at 010-89281810-808 or via email at investor@succeeder.com.cn [6]. - After the meeting, the main content and outcomes will be available on the Shanghai Stock Exchange Roadshow Center [6].